RT期刊文章SR电子T1打破抽象——皮质类固醇优化后期严重哮喘使用复合生物标志物来调整剂量和症状/风险算法摩根富林明欧洲呼吸杂志乔和J FD欧洲呼吸学会SP 4618欧元做10.1183/13993003.国会- 2020.4618 VO 56 5 64 A1蒂姆Hardman A1利希尼A1约翰·巴斯比A1凯瑟琳A1韩瑞提姆也有A1阿什利丘鹬A1萨曼莎沃克A1约瑟夫炎亚纶A1大卫白菜A1彼得·布拉德A1克里斯托弗Brightling A1 Rehka乔杜里A1道格拉斯188bet官网地址·考恩A1罗布尼文A1斯蒂芬·福勒A1蒂姆·哈里森A1彼得•豪沃思A1吉姆Lordan A1阿德尔曼苏尔A1安德鲁Menzies-Gow A1道格拉斯·罗宾逊年2020 UL //www.qdcxjkg.com/content/56/suppl_64/4618.abstract AB简介:增加皮质类固醇(CS)控制哮喘症状和发作有潜力不高,难以down-titrate CS剂量。目标和目标:我们测试是否T2 biomarker-based策略(BS)指导降低CS(保理分式呼出一氧化氮(FeNO),血液嗜酸性粒细胞,血清periostin)和症状控制会看到更少的加重和更好的哮喘控制和肺功能。方法:随机(4:1 / BS:控制),单盲平行组试验中,患者(pts)严重哮喘和FeNO < 45磅的组特定指令CS调整每8周内。主要结果是分的比例实现CS Wk48减少。二次结果包括恶化率、肺功能和哮喘控制。结果:意向处理人口(240 BS和61控制分),BS的比例分在CS低剂量Wk48在控件(28.4%比18.5%或调整:1.71;95% ci 0.80, 3.63;p = 0.165)。在每个协议(PP)人口(n = 121),更分在Wk48 CS剂量较低的废话和对照组(30.7%比5.0% (OR: 11.48;95% ci 1.35, 97.83;p = 0.026)。未能遵循治疗建议ITT和PP人口差异的主要原因。 There was no difference in secondary outcomes between study arms.Conclusion: Biomarker based CS adjustment did not result in a greater proportion of pts reducing CS vs. control, probably because many pts did not follow treatment advice. The biomarker strategy seemed beneficial in pts where symptoms and T2 biomarker profile were discordant.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4618.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).